Research Alliance V proposes $62,000,000 share offering

Research Alliance Corporation V proposes selling 6,200,000 ordinary shares at $10.00 each, according to its SEC prospectus. The acquisition vehicle lists a proposed Nasdaq symbol of RACV and seeks businesses with drug candidates or platforms supported by scientific data and a path toward further clinical development. Its sponsor has indicated interest in purchasing up to $100.0 million of additional shares when an initial business combination closes. That indication is nonbinding, and neither side is obligated to proceed. Investors in the public offering would receive no warrants.